- Home
- ORI vs JAZZ Comparison
ORI vs JAZZ Comparison
Compare ORI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORI | JAZZ |
|---|---|---|
| Founded | 1923 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.8B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | ORI | JAZZ |
|---|---|---|
| Price | $45.36 | $167.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $49.00 | ★ $199.20 |
| AVG Volume (30 Days) | ★ 1.8M | 1.6M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $8,748,900,000.00 | $4,157,832,999.00 |
| Revenue This Year | $10.22 | $6.00 |
| Revenue Next Year | $6.10 | $6.84 |
| P/E Ratio | $13.66 | ★ N/A |
| Revenue Growth | ★ 7.08 | 4.14 |
| 52 Week Low | $33.00 | $95.49 |
| 52 Week High | $46.63 | $182.99 |
Technical Indicators
Market Signals| Indicator | ORI | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 61.12 | 57.75 |
| Support Level | $43.12 | $161.00 |
| Resistance Level | $43.85 | $168.69 |
| Average True Range (ATR) | 0.72 | 4.96 |
| MACD | -0.15 | -1.99 |
| Stochastic Oscillator | 67.48 | 30.32 |
Price Performance
Historical ComparisonAbout ORI Old Republic International Corporation
Old Republic International Corp offers a diverse range of specialized insurance products to individuals and institutions. The company operates in two segments: Specialty Insurance and Title Insurance. The Insurances provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.